NEW YORK – Macrogen said on Monday that it has signed a strategic license and supply agreement for capillary electrophoresis sequencing technology with Thermo Fisher Scientific.
The Korean company said it plans to use equipment and reagents from Thermo Fisher and to expand its overseas markets for CE sequencing services. As part of that, it has established laboratories in Spain and in Singapore and plans to open additional labs in Oceania and Europe.
"Macrogen is preparing to take the next big step in the market for [CE sequencing], which has been key to the company's initial growth and is growing rapidly thanks to the expansion of related applications," said Kap-Seok Yang, the company's CEO, in a statement. "Our agreement with global bio market leader Thermo Fisher Scientific will allow Macrogen to pursue global marketing that addresses the ongoing changes in the [CE sequencing] market."